前言 ①数字货币+区块链+华为+数据要素！这家公司在数字货币方面有较深的技术储备；②PCB概念+芯片+光 刻胶+光伏！这家公司与主流PCB制造厂商建立稳定供货关系；③芯片+合成生物+氢能源+储能！公司现 金收购半导体企业股权。 每周日至每周四推送明日股市重大公告！内容包含"停复牌、增减持、投资中标、收购、业绩、解禁、 高送转"等一系列个股利好利空公告，其中重要公告均以红色标注，帮助投资者提前寻找到投资热点， 防范各类黑天鹅事件，并且有充足的时间进行分辨和寻找合适的上市公司。 ...

An updated edition of the May 21, 2025, article.The promising field of genomics has undergone rapid evolution over the past decade. Genomics includes the study of a complete set of genes, their work process and way of interacting with each other and the environment. The primary focus is to evaluate all the genes of an organism rather than individual genes.This genetic information is being used to evaluate individual responses to drugs, leading to the development of targeted therapies. This, in turn, has pav ...

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The company will present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference, highlighting its innovative approach to tumor-specific therapies [1] Company Overview - Senti Bio is dedicated to creating new cell and gene therapies for patients with incurable diseases, utilizing synthetic biology to engineer Gene Circuits for enhanced precision and control [3] - The company's pipeline includes cell therapies designed to target both liquid and solid tumors, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [3] Conference Details - The SEED Conference, established in 2014, serves as a premier event for synthetic biologists, facilitating networking and collaboration among over 5,000 professionals in the field [1] - Senti Bio's presentation will focus on "Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated Cells," showcasing its advancements in the field [1]

以下文章来源于LP波谱 ，作者杨博宇 LP波谱 . 本账号专注LP市场报道。"波浪、谱系"是识别市场的维度，也是定义市场的坐标；此外，波谱（Pop Art）也意为放低意义与史诗的执念，认同商业的日常之美。 将投中网设为"星标⭐"，第一时间收获最新推送 包括广东的消息在内，本周LP圈共有17条动态。其中朝希资本完成7亿元募资；14支新基金成立，南 京浦口区、宿迁宿城区正在遴选GP。推荐关注20亿规模的杭州西湖未来基金、湖北50亿人形机器人 产投基金等。 募资动态 聚焦LP出资、新基金、GP招募，捕捉LP圈一周商业情报。 作者丨杨博宇 来源丨LP波谱 广东在今年3月组建了首支AIC人工智能产业基金，中国工商银行广东省分行、工银金融资产投资有 限公司和广东恒健投资控股有限公司联合出资，其规模达100亿，面向AI与机器人产业投资。 而在本周，押注AI产业的热情再度高涨。广东推动广东民营投资股份有限公司、国科私募基金、商 汤集团、佳都科技、澳门礼达控股、新方盛集团等民营资本、港澳资本合作设立了总规模100亿的广 东省智能产业基金，投资方向也主要是AI、机器人、芯片半导体等领域。 两支百亿基金相继设立，体现了广东对发展A ...

当前，国际合成生物学优势力量主要分布在美、欧等地，其政策对我国来说具备一定参考意义，国内也 正以省市为单位进行政策端布局、提供路线指导与各类支持，随着生物制造产业落地的需求不断变强， 新的纲领性文件有望出现，进一步指导行业发展、完成合成生物学产业的健康价值循环。另一方面，通 过机器学习模型和算法，AI可以在短时间内分析大量数据并对生物系统进行建模、仿真，从而快速评 估设计方案和实验条件、预测与优化研发结果，减少实验的盲目性和重复性，随着国内AI技术不断发 展，其将为合成生物学的研究提供有力支持。 华安证券（600909）发布研报称，合成生物学作为融合多学科的颠覆性技术，正推动生物制造成为化工 产业转型升级的新方向。AI技术通过建模仿真大幅提升研发效率，国内算法进步将持续赋能合成生物 学研究。当前全球合成生物学产业处于高速发展期，国内政策端持续加码，AI技术赋能研发效率提 升，产业链各环节均孕育丰富投资机会。 华安证券主要观点如下： 合成生物学是生产力转型升级新方向 合成生物学是一门基于工程化的设计理念，结合生物学、化学、医学、农学、工程学、计算机与数据科 学等交叉学科技术，旨在设计和构建新的生物系统，以实现特 ...

Industry Overview - The rapid evolution of genomics is leading to a revolutionary era in genetic medicine, driven by the need for innovative medical treatments [1] - Genomics focuses on the complete set of genes and their interactions, rather than individual genes, which is attracting attention from pharma and biotech companies [2] - Breakthroughs in genomics have enabled the development of targeted therapies based on individual genetic information [2] - The genomics market is projected to reach $157.47 billion by 2033, while the global synthetic biology market was valued at $16.22 billion in 2024 and is expected to grow at a CAGR of 17.30% from 2025 to 2030 [6] Key Companies - Illumina (ILMN) is a major player in the genomics sector, known for its sequencing and array-based solutions for genetic analysis [4] - Gene editing companies like BEAM Therapeutics (BEAM) and CRISPR Therapeutics AG (CRSP) are developing technologies such as CRISPR/Cas9 to treat diseases caused by genetic variants [5] Investment Opportunities - Intellia Therapeutics (NTLA) is focused on CRISPR-based therapies for diseases with high unmet needs, with lead candidates in phase III studies [8][9] - uniQure (QURE) is advancing gene therapies for conditions like Huntington's disease and has received Breakthrough Therapy designation for AMT-130 [11][12] - Verve Therapeutics (VERV) is developing gene editing medicines for cardiovascular disease, targeting genes like PCSK9 and ANGPTL3 [14][15]

Industry Background - In 2025, the food industry is influenced by various factors including policy, economy, social structure, and technology, showcasing unique development trends and consumption patterns [2][4] - The government prioritizes "boosting consumption" as a key task, aiming to transition the food industry from "recovery growth" to "high-quality development" [2][4] - The GDP growth for 2024 is projected at 5%, but the food industry's added value has been declining for four consecutive years, indicating structural supply-demand issues [2][4] - The aging population is accelerating, with those aged 65 and above accounting for 15.6% of the population, while urbanization has reached 67%, shifting consumer dietary preferences from "sufficient" to "quality" [2][4] Core Consumption Trends - Six core consumption trends are identified as new directions for industry development: 1. **Diverse Channel Innovations**: 84.2% of consumers are purchasing alternative products, with retailers optimizing supply chains to lower prices and enhance value [3] 2. **Precision Nutrition Products**: New products targeting different age groups, including senior nutrition and children's dietary needs, are emerging [3] 3. **Emotional Value Experiences**: Marketing strategies focus on sensory and situational engagement, enhancing consumer emotional experiences [3] 4. **Key Demographic Opportunities**: Brands are targeting family nutrition, with rapid growth in urban markets and services for overseas tourists [3] 5. **Smart Information Experiences**: AI is being integrated into product development and production, enhancing personalized nutrition services [3] 6. **Green Revolution in Food and Beverage**: Transparency in supply chains and innovations in green packaging are gaining traction, with over 70% of consumers concerned about "no additives" [3] Strategic Focus for 2025 - The food industry must focus on channel efficiency, precision nutrition, and emotional value, leveraging AI and green technologies to address the needs of the aging population and urban-rural integration [4][5] - The transition from scale expansion to value creation is essential for building a sustainable development ecosystem [4][5]

Grow with Ginkgo Q1 2025 Update & Business Review May 6, 2025 Property of Ginkgo Bioworks — 1 Q1 2025 UPDATE & BUSINESS REVIEW Disclaimer FORWARD-LOOKING STATEMENTS This presentation, the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the tim ...

Fiscal 2025 2Q Financial Results M A Y 2 0 2 5 Agenda Welcome Angela Bitting SVP, Corporate Affairs 2 | TWIST BIOSCIENCE | PROPRIETARY Quarterly Highlights Emily Leproust Chief Executive Officer Business Highlights Patrick Finn President and Chief Operating Officer Financial and Operational Performance Adam Laponis Chief Financial Officer Milestones Emily Leproust Chief Executive Officer Q&A Session Legal Disclaimers This presentation contains forward-looking statements. All statements other than statements ...

Core Insights - The 66th National Pharmaceutical Machinery Exposition successfully concluded on April 25, 2025, at Chongqing International Expo Center, organized by HAINAN JING-BO-XIN EXHIBITION CO., LTD. [1] - The exposition attracted 1,686 exhibitors from 24 countries and regions, showcasing over 10,000 products across an exhibition space of 180,000 square meters, with more than 60,000 visitors from 88 countries and regions [3]. Industry Overview - The exposition included a Malaysia-China procurement matchmaking session, facilitating one-on-one meetings between over 20 Chinese manufacturers and six Malaysian pharmaceutical companies [3]. - The organizing committee hosted three thematic forums and 93 technical exchange sessions, featuring keynote speeches from renowned experts and industry professionals [4]. - The Second CIPM Synthetic Biology and Biomanufacturing Industry Development Conference was a significant highlight, attracting over 1,000 professionals from various sectors including pharmaceuticals, food, cosmetics, and pesticides [4]. Historical Context - The China National Pharmaceutical Machinery Exposition has been held biannually since the 1990s and has been recognized as a key exhibition supported by China's Ministry of Commerce since 2004 [5]. - The event expanded in 2008 to include the China International Pharmaceutical Machinery Exposition (CIPM), covering production, processing, packaging, testing, and auxiliary equipment for various industries [5]. - Over the years, CIPM has evolved into a premier global event that integrates trade, technology exchange, and industry dialogue [5].